VERAXA Biotech Appoints Raju Willener as CFO to Strengthen Capital Strategy and Advance Oncology Pipeline

VERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based cancer therapies, has announced the appointment of Raju Willener as its new chief financial officer, effective immediately. The appointment signals the company's intent to strengthen its financial leadership as it advances its proprietary BiTAC technology platform and oncology pipeline. Willener brings more than three decades of international financial leadership experience, encompassing global capital markets, investment banking, corporate finance, asset management, and strategic leadership. He will report directly to CEO and Co-Founder Christoph Antz, Ph.D., and is expected to play a key role in shaping the company's capital strategy and identifying strategic opportunities.

Willener's extensive background includes serving as director of corporate development at Exentis Group AG, where he was appointed CFO in 2025. At Exentis, he led mergers and acquisitions initiatives, financial strategy, and key corporate functions. Earlier in his career, he held senior executive and investment positions, overseeing areas such as corporate finance, capital markets, investor relations, and investment portfolios exceeding CHF 30 billion in assets under management. His deep understanding of the financial landscape is anticipated to be instrumental as VERAXA continues to develop its pipeline of bispecific T cell engagers, bispecific antibody-drug conjugates (ADCs), and other innovative antibody-based therapeutics.

VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company is dedicated to building a premier engine for the discovery and development of next-generation antibody-based therapeutics. With its suite of transformative technologies and rigorous quality-by-design principles, VERAXA is rapidly advancing its pipeline into clinical development and beyond. The BiTAC technology platform, a registered trademark of VERAXA Biotech GmbH, is central to the company's approach to creating potent cancer therapies.

The appointment of Raju Willener comes at a critical juncture for VERAXA as it seeks to navigate the complex financial landscape of the biotech industry. His expertise in capital markets and corporate finance is expected to provide the strategic guidance needed to secure funding and drive the company's growth. This move underscores VERAXA's commitment to building a strong leadership team capable of executing its vision of delivering transformative cancer treatments. For more information about VERAXA Biotech and its latest developments, visit the company's newsroom at http://nnw.fm/VRXA.